Knockdown of prohibitin 2 promotes apoptosis in non-small cell lung cancer cell line A549

doi:10.16352/j.issn.1001-6325.2023.10.1522

Abstract

Abstract: Objective To explore mechanism of prohibitin 2(PHB2) inhibition on the apoptosis of non-small cell lung cancer cell line A549. Methods For stable knockdown of PHB2, A549 strain was infected with lentiviruses. A549 cells with PHB2 depletion were incubated with Mdivi-1(DRP1 inhibitor). Apoptotic index of A549 cells was evaluated by TUNEL and annexin V-FITC/PI. Mitochondrial morphology was visualized by MitoTracker. ATP content, citrate synthase activity and the level of cytochrome c in cytosolic and mitochondrial fractions were analyzed by commercially available kits. Western blot was used to measure the levels of PHB2, DRP1 and p-DRP1 protein expression. Results Compared with the shCtrl group, the apoptosis of A549 cells increased significantly (P＜0.05) with up-regulated DRP1-dependent mitochondrial fission (P＜0.05), down-regulated ATP content (P＜0.05) and citrate synthase activity (P＜0.05). The level of cytochrome C was decreased in mitochondrial fractions (P＜0.05). Compared with the shPHB2 group, the apoptosis of A549 cells decreased significantly (P＜0.05) with alleviated DRP1-dependent mitochondrial fission (P＜0.05), increase of ATP content (P＜0.05) and citrate synthase activity(P＜0.05). The level of cytochrome C was increased in mitochondrial fractions (P＜0.05) in the shPHB2+Mdivi-1 group. Conclusions PHB2 inhibition can significantly enhance the apoptosis rate of A549 cells, potentially through promoting DRP1-dependent mitochondrial fission.

Key words: prohibitin 2(PHB2), mitochondrial fission, non-small cell lung cancer, dynamin-related protein 1(DRP1), apoptosis

CLC Number:

R734.2

ZHANG Jing, YANG Zigeng, WEI Hongmei, NING Haihong, XUE Xixi, JIN Ling, WU Bin. Knockdown of prohibitin 2 promotes apoptosis in non-small cell lung cancer cell line A549[J]. Basic & Clinical Medicine, 2023, 43(10): 1522-1529.

References 15

[1]	Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021[J]. CA Cancer J Clin, 2021,71:7-33.
[2]	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021,71:209-249.
[3]	薛剑超, 王亚东, 李博文, 等. DNA甲基化在肺癌发生及预后中作用的研究进展[J]. 基础医学与临床, 2023,43:514-518.
[4]	任孟先, 梁伟, 刘艳. 塞来昔布联合IMRT对老年中晚期非小细胞肺癌患者免疫功能和血清肿瘤标志物的影响[J]. 基础医学与临床, 2021,41:890-894.
[5]	Signorile A, Sgaramella G, Bellomo F, et al. Prohibitins: a critical role in mitochondrial functions and implication in diseases[J]. Cells, 2019,8:278-286.
[6]	Wu B, Chang N, Xi H, et al. PHB2 promotes tumorigenesis via RACK1 in non-small cell lung cancer[J]. Theranostics, 2021,11:3150-3166.
[7]	Kasashima K, Ohta E, Kagawa Y, et al. Mitochondrial functions and estrogen receptor-dependent nuclear translocation of pleiotropic human prohibitin 2[J]. J Biol Chem, 2006,281:36401-36410.
[8]	Cai XW, Yu WW, Yu W, et al. Tissue-based quantita-tive proteomics to screen and identify the potential biomarkers for early recurrence/metastasis of esophageal squamous cell carcinoma[J]. Cancer Med, 2018,7:2504-2517.
[9]	Cheng J, Gao F, Chen X, et al. Prohibitin-2 promotes hepatocellular carcinoma malignancy progression in hypoxia based on a label-free quantitative proteomics strategy[J]. Mol Carcinog, 2014,53:820-832.
[10]	Cao Y, Liang H, Zhang F, et al. Prohibitin overexpres-sion predicts poor prognosis and promotes cell proliferation and invasion through ERK pathway activation in gallbl-adder cancer[J]. J Exp Clin Cancer Res, 2016,35:68-78.
[11]	Yapa N, Lisnyak V, Reljic B, et al. Mitochondrial dynamics in health and disease[J]. FEBS Lett, 2021,595:1184-1204.
[12]	Srinivasan S, Guha M, Kashina A, et al. Mitochondrial dysfunction and mitochondrial dynamics-the cancer connection[J]. Biochim Biophys Acta Bioenerg, 2017,1858:602-614.
[13]	Willems PH, Rossignol R, Dieteren CE, et al. Redox homeostasis and mitochondrial dynamics[J]. Cell Metab, 2015,22:207-218.
[14]	Serasinghe MN, Chipuk JE. Mitochondrial fission in human diseases[J]. Handb Exp Pharmacol, 2017,240:159-188.
[15]	Wu B, Xiong J, Zhou Y, et al. Luteolin enhances TRAIL sensitivity in non-small cell lung cancer cells through increasing DR5 expression and Drp1-mediated mitochondrial fission[J]. Arch Biochem Biophys, 2020,692:108539-108543.